184 related articles for article (PubMed ID: 30314880)
1. Design of novel lipidated peptidomimetic conjugates for targeting EGFR heterodimerization in HER2 + cancer.
Naik H; Gauthier T; Singh S; Jois S
Bioorg Med Chem Lett; 2018 Dec; 28(22):3506-3513. PubMed ID: 30314880
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of peptidomimetics that inhibit PPI of HER2-HER3.
Kanthala S; Gauthier T; Satyanarayanajois S
Biopolymers; 2014 Jun; 101(6):693-702. PubMed ID: 24222531
[TBL] [Abstract][Full Text] [Related]
3. A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models.
Singh SS; Mattheolabakis G; Gu X; Withers S; Dahal A; Jois S
Eur J Med Chem; 2021 Apr; 216():113312. PubMed ID: 33667849
[TBL] [Abstract][Full Text] [Related]
4. Design of cyclic and d-amino acids containing peptidomimetics for inhibition of protein-protein interactions of HER2-HER3.
Pallerla S; Naik H; Singh S; Gauthier T; Sable R; Jois SD
J Pept Sci; 2018 Feb; 24(2):. PubMed ID: 29436155
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of protein-protein interaction of HER2-EGFR and HER2-HER3 by a rationally designed peptidomimetic.
Banappagari S; Corti M; Pincus S; Satyanarayanajois S
J Biomol Struct Dyn; 2012; 30(5):594-606. PubMed ID: 22731912
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and characterization of peptidomimetic conjugate of BODIPY targeting HER2 protein extracellular domain.
Banappagari S; McCall A; Fontenot K; Vicente MG; Gujar A; Satyanarayanajois S
Eur J Med Chem; 2013 Jul; 65():60-9. PubMed ID: 23688700
[TBL] [Abstract][Full Text] [Related]
7. Novel Peptidomimetics for Inhibition of HER2:HER3 Heterodimerization in HER2-Positive Breast Cancer.
Kanthala S; Banappagari S; Gokhale A; Liu YY; Xin G; Zhao Y; Jois S
Chem Biol Drug Des; 2015 Jun; 85(6):702-714. PubMed ID: 25346057
[TBL] [Abstract][Full Text] [Related]
8. Design of a doxorubicin-peptidomimetic conjugate that targets HER2-positive cancer cells.
Pallerla S; Gauthier T; Sable R; Jois SD
Eur J Med Chem; 2017 Jan; 125():914-924. PubMed ID: 27769032
[TBL] [Abstract][Full Text] [Related]
9. A peptidomimetic with a chiral switch is an inhibitor of epidermal growth factor receptor heterodimerization.
Kanthala SP; Liu YY; Singh S; Sable R; Pallerla S; Jois SD
Oncotarget; 2017 Sep; 8(43):74244-74262. PubMed ID: 29088782
[TBL] [Abstract][Full Text] [Related]
10. A conformationally constrained peptidomimetic binds to the extracellular region of HER2 protein.
Banappagari S; Ronald S; Satyanarayanajois SD
J Biomol Struct Dyn; 2010 Dec; 28(3):289-308. PubMed ID: 20919746
[TBL] [Abstract][Full Text] [Related]
11. Design of peptidomimetics for inhibition of HER2 receptor dimerization by a combination of virtual screening, MD simulations, and QSAR in silico methods.
Jamalan M; Zeinali M; Barzegari Asadabadi E
Chem Biol Drug Des; 2013 Apr; 81(4):455-62. PubMed ID: 23006820
[TBL] [Abstract][Full Text] [Related]
12. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
[TBL] [Abstract][Full Text] [Related]
13.
Shrestha L; Singh SS; Parajuli P; Dahal A; Mattheolabakis G; Meyer S; Bhattacharjee J; Jois SD
J Cancer; 2020; 11(20):5982-5999. PubMed ID: 32922539
[TBL] [Abstract][Full Text] [Related]
14. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.
Banappagari S; Ronald S; Satyanarayanajois SD
Medchemcomm; 2011 Jan; 2(8):752-759. PubMed ID: 21887403
[TBL] [Abstract][Full Text] [Related]
16. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
[TBL] [Abstract][Full Text] [Related]
17. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
[TBL] [Abstract][Full Text] [Related]
18. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and docking studies of peptidomimetics based on HER2-herceptin binding site with potential antiproliferative activity against breast cancer cell lines.
Satyanarayanajois S; Villalba S; Jianchao L; Lin GM
Chem Biol Drug Des; 2009 Sep; 74(3):246-57. PubMed ID: 19703026
[TBL] [Abstract][Full Text] [Related]
20. Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.
Ellebaek S; Brix S; Grandal M; Lantto J; Horak ID; Kragh M; Poulsen TT
Int J Cancer; 2016 Nov; 139(9):2095-105. PubMed ID: 27342948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
